Antonio CapalboJune 22, 2017
Jan BrosensDecember 15, 2016
Herjan Coelingh Bennink, The Netherlands
Herjan Coelingh Bennink (HCB), MD, PhD
, trained in Gynaecology and Internal Medicine in Leiden and in Utrecht, the Netherlands and certified in 1976 as specialist in ObGyn. Since 1976 he was director of the Department of Reproductive Endocrinology at the University Hospital in Utrecht. In 1987 he joined Organon in the Netherlands as Executive VP of the Women’s Health R&D programme and developed drugs such as Puregon and Antagon for IVF, the Nuvaring, the Implanon and Cerazette for contraception and Livial (tibolone) for HRT. From 1997-2005 HCB was professor WH at the Dutch speaking Free University in Brussels, Belgium.
HCB founded Pantarhei Bioscience in 2001 for the development of new drugs for WH applications, such as the natural fetal steroid Estetrol (E4) and a new oral contraceptive preserving sexual function (Androgen Restored Contraception). In 2014 HCB founded Pantarhei Oncology for the development of drugs for endocrine and reproductive tract cancers such as an immunological method for the treatment of Zona Pellucida (ZP) antigen expressing cancers and E4 for the treatment of breast and prostate cancer.